Menu
Glycanostics is an innovative start-up company established in 2017 to deliver its revolutionary cancer products to the EU and USA markets. Our patented technology for screening cancer detects changes in a glycan (complex carbohydrates) attached to a protein in the blood. It is highly innovative thanks to the following unique characteristics: it detects early-stage cancers that can be missed by imaging techniques; it gives quantitative & qualitative information, so progress of the disease can be monitored; it is affordable, without the need for complex equipment; it is rapid, easy, accessible and only minimally invasive; it reduces the number of false-positive results which can lead to unnecessary imaging, re-imaging and/or biopsies; it is fully compatible with automatic equipment already used by laboratories worldwide, and is potentially applicable to the screening of several cancer types.
We have received funding from the prestigious EIC Accelerator funding scheme to support full test development, clinical validation, and CE certification of the prostate cancer diagnostic test. We also received a Seal of Excellence from the EIC Transition funding scheme to further extend the portfolio of products for diagnostics of breast, lung, and pancreatic cancers.
We would highly appreciate collaboration with clinical laboratories and hospitals to obtain serum samples for clinical validations and with clinicians/oncologists to address clinical needs.
Pancreatic cancer is seldom detected at its early stages when it could be curable. This is because it often displays no symptoms until it has spread to other organs. As a result, 5 year survival is as low as 10%.
The early detection of pancreatic cancer is likely to result in a significant improvement in overall survival.
Help us to save lives by early-stage and highly accurate cancer diagnostics.
Lung cancer is the second most frequent malignancy worldwide, counting 2,2M new cases and causing 1,7M deaths in 2020.
Estimated number of new cases is expected to increase to 3,4M cases, with 2,9M annual deaths by 2040. The expected increase is more than 55%. Similar to pancreatic cancer, it is often detected at a late stage, when the chances for survival are much lower.
Help us to save lives by early-stage and highly accurate cancer diagnostics
Breast cancer is the first most frequent malignancy in women worldwide.
Developments in research have led to emerging therapies that attack breast cancer tumors in innovative ways, such as genetic profiling, proton radiation, and immunotherapy.
The fight against breast cancer has converted what was once a terminal illness into a survivable health event, if treated early.
Higher accuracy in early cancer diagnostics brings fewer radical surgeries, innovative therapies and more quality of live for woman. Our test may take breast cancer screenings to the next level.
Help us to save lives by early-stage and highly accurate cancer diagnostics.
